Table 2.
Treatment administration and response by minority race
| All (N = 88) | Black (N = 36) | Hispanic (N = 43) | Othera (N = 9) | |
|---|---|---|---|---|
| Treatment administration | ||||
| Days to treatment initiationb, median (IQR) | 31 (40) | 40 (34) | 24 (52) | 31 (15) |
| Chemotherapy | 87 (98.9) | 35 (97.2) | 43 (100) | 9 (100) |
| Fluoropyrimidinec | 87 (100) | 35 (100) | 43 (100) | 9 (100) |
| Oxaliplatin | 83 (95.4) | 34 (97.1) | 41 (95.4) | 8 (88.9) |
| Irinotecan | 49 (56.3) | 19 (54.3) | 25 (58.1) | 5 (55.6) |
| Bevacizumab | 53 (60.9) | 26 (74.3) | 21 (48.8) | 6 (66.7) |
| EGFR inhibitord (N = 47) | 29 (61.7) | 7 (41.2) | 17 (73.9) | 5 (71.4) |
| Regorafenib | 6 (6.9) | 5 (14.3) | 1 (2.3) | 0 (0.0) |
| Radiation therapy | 22 (25.0) | 9 (25.0) | 10 (23.3) | 3 (33.3) |
| Surgical therapy | 37 (42.0) | 17 (47.2) | 16 (37.2) | 4 (44.4) |
| Primary tumor resection | 34 (91.9) | 16 (94.1) | 15 (93.8) | 3 (75.0) |
| Metastatic resection | 12 (32.4) | 3 (17.7) | 6 (37.5) | 3 (75.0) |
| Other therapye | 6 (6.8) | 2 (5.6) | 2 (4.7) | 2 (22.2) |
| Response to chemotherapy | ||||
| First response | ||||
| Complete response | 3 (3.4) | 1 (2.9) | 1 (2.3) | 1 (11.1) |
| Partial response | 46 (52.9) | 17 (48.6) | 24 (55.8) | 5 (55.6) |
| Stable disease | 13 (14.9) | 9 (25.7) | 4 (9.3) | 0 (0.0) |
| Disease progression | 16 (18.4) | 6 (17.1) | 9 (20.9) | 1 (11.1) |
| No restaging | 9 (10.3) | 2 (5.7) | 5 (11.6) | 2 (22.2) |
| Disease control rate (%) | 79.5 | 81.8 | 76.3 | 85.7 |
| Response rate (%) | 62.8 | 54.6 | 65.8 | 85.7 |
| Best response | ||||
| Complete response | 6 (6.9) | 2 (5.7) | 3 (7.0) | 1 (11.1) |
| Partial response | 46 (52.9) | 18 (51.4) | 23 (53.5) | 5 (55.6) |
| Stable disease | 16 (18.4) | 8 (22.9) | 8 (18.6) | 0 (0.0) |
| Disease progression | 10 (11.5) | 5 (14.3) | 4 (9.3) | 1 (11.1) |
| No restaging | 9 (10.3) | 2 (5.7) | 5 (11.6) | 2 (22.2) |
| Disease control rate (%) | 87.2 | 84.9 | 89.5 | 85.7 |
| Response rate (%) | 66.7 | 60.6 | 68.4 | 85.7 |
a
Includes Asian, Middle Eastern
b
Defined as initiation of non-emergent chemotherapy, radiation therapy, or surgical resection
c
Infusional 5-fluorouracil or capecitabine
d
For KRAS wild type tumors
e
Includes radiofrequency ablation, microwave ablation, and portal vein embolization for liver metastases